Страна: Австралия
Язык: английский
Источник: Department of Health (Therapeutic Goods Administration)
potassium clavulanate, Quantity: 151.917 mg; amoxicillin trihydrate, Quantity: 573.892 mg
Arrotex Pharmaceuticals Pty Ltd
amoxicillin trihydrate,potassium clavulanate
Tablet, film coated
Excipient Ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; dichloromethane; isopropyl alcohol; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose
Oral
10 tablets
(S4) Prescription Only Medicine
AMCLAVOX DUO 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to Microbiology):,Urinary Tract Infections (complicated and uncomplicated),Lower Respiratory Tract Infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,Upper Respiratory Tract Infections, such as sinusitis, otitis media and recurrent tonsillitis.,Skin and Skin Structure Infection.,Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. However, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate. The treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.
Visual Identification: White colored capsule shaped film coated tablet debossed with 'I 06' on one side and plain on other side.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius
Licence status A
2017-08-07
AMCLAVOX DUO 500/125 & AMCLAVOX DUO FORTE 875/125 TABLETS Amoxicillin and clavulanic acid CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? Please read this leaflet carefully before you take AMCLAVOX DUO & AMCLAVOX DUO FORTE tablets. This leaflet answers some common questions about AMCLAVOX DUO & AMCLAVOX DUO FORTE tablets. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Sometimes new risks are found even when a medicine has been used for many years. Your doctor has weighed the expected benefits of you taking AMCLAVOX DUO & AMCLAVOX DUO FORTE tablets against the risks this medicine could have for you. If you have any concerns about taking this medicine, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again. WHAT ARE AMCLAVOX DUO & AMCLAVOX DUO FORTE TABLETS USED FOR? AMCLAVOX DUO & AMCLAVOX DUO FORTE tablets contain two active ingredients. One of these is a penicillin called amoxicillin and the other is clavulanic acid. AMCLAVOX DUO & AMCLAVOX DUO FORTE tablets belong to the penicillin group of antibiotics. AMCLAVOX DUO & AMCLAVOX DUO FORTE tablets are used for the short-term treatment of a wide range of infections caused by bacteria. These infections may affect the chest (e.g. bronchitis or pneumonia), bladder (e.g. cystitis), sinuses (e.g. sinusitis), the ears (e.g. otitis media) or the skin. AMCLAVOX DUO & AMCLAVOX DUO FORTE tablets work by killing the bacteria that cause these infections. AMCLAVOX DUO & AMCLAVOX DUO FORTE tablets will not work against infections caused by viruses such as colds or the flu. Your doctor may prescribe AMCLAVOX DUO & AMCLAVOX DUO FORTE tablets for another use. If you want more information, ask your doctor. There is no evidence that AMCLAVOX DUO & AMCLAVOX DUO FORTE tablets are addictive. BEFORE YOU TAKE AMCLAVOX DUO & AMCLAVOX DUO FORTE TABLETS _Do not take AMCLAVOX _ _DUO & AMCLAVOX _ _DUO FORTE tablets if: _ • You hav Прочитать полный документ
1 AUSTRALIAN PRODUCT INFORMATION – AMCLAVOX DUO 500/125 & AMCLAVOX DUO FORTE 875/125 (AMOXICILLIN AND CLAVULANIC ACID) TABLETS 1 NAME OF THE MEDICINE Amoxicillin trihydrate and potassium clavulanate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION AMCLAVOX DUO 500 /125 tablets contain amoxicillin (as trihydrate) 500 mg and clavulanic acid (as potassium clavulanate) 125 mg. AMCLAVOX DUO FORTE 875 /125 tablets contain amoxicillin (as trihydrate) 875 mg and clavulanic acid (as potassium clavulanate) 125 mg. AMCLAVOX DUO 500 / 125 and AMCLAVOX DUO FORTE 875 / 125 contain 25 mg potassium per tablet. For the full list of excipients see SECTION 6.1 LIST OF EXCIPIENTS 3 PHARMACEUTICAL FORM AMCLAVOX DUO 500 /125 tablets are white coloured capsule shaped film coated tablets debossed with ‘Ɩ 06’ on one side and plain on other side. AMCLAVOX DUO FORTE 875 /125 tablets are white coloured capsule shaped film coated tablets debossed with ‘Ɩ 07’ on one side and plain on other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS AMCLAVOX DUO tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to Microbiology): • Urinary Tract Infections (complicated and uncomplicated) • Lower Respiratory Tract Infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. • Upper Respiratory Tract Infections, such as sinusitis, otitis media and recurrent tonsillitis. • Skin and Skin Structure infections. Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. However, when there is reason to believe an infection may involve any of the β-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate. 2 The treatment of mixed Прочитать полный документ